BACKGROUND: Pancreatic ductal adenocarcinoma remains one of the most lethal malignancies, with few treatment options. NAPOLI 3 aimed to compare the efficacy and safety of NALIRIFOX versus nab-paclitaxel and gemcitabine as first-line therapy for metastatic pancreatic ductal adenocarcinoma (mPDAC). METHODS: NAPOLI 3 was a randomised, open-label, phase 3 study conducted at 187 community and academic sites in 18 countries worldwide across Europe, North America, South America, Asia, and Australia. Patients with mPDAC and Eastern Cooperative Oncology Group performance status score 0 or 1 were randomly assigned (1:1) to receive NALIRIFOX (liposomal irinotecan 50 mg/m2, oxaliplatin 60 mg/m2, leucovorin 400 mg/m2, and fluorouracil 2400 mg/m2, administered sequentially as a continuous intravenous infusion over 46 h) on days 1 and 15 of a 28-day cycle or nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2, administered intravenously, on days 1, 8, and 15 of a 28-day cycle. Balanced block randomisation was stratified by geographical region, performance status, and liver metastases, managed through an interactive web response system. The primary endpoint was overall survival in the intention-to-treat population, evaluated when at least 543 events were observed across the two treatment groups. Safety was evaluated in all patients who received at least one dose of study treatment. This completed trial is registered with ClinicalTrials.gov, NCT04083235. FINDINGS: Between Feb 19, 2020 and Aug 17, 2021, 770 patients were randomly assigned (NALIRIFOX, 383; nab-paclitaxel-gemcitabine, 387; median follow-up 16·1 months [IQR 13·4-19·1]). Median overall survival was 11·1 months (95% CI 10·0-12·1) with NALIRIFOX versus 9·2 months (8·3-10·6) with nab-paclitaxel-gemcitabine (hazard ratio 0·83; 95% CI 0·70-0·99; p=0·036). Grade 3 or higher treatment-emergent adverse events occurred in 322 (87%) of 370 patients receiving NALIRIFOX and 326 (86%) of 379 patients receiving nab-paclitaxel-gemcitabine; treatment-related deaths occurred in six (2%) patients in the NALIRIFOX group and eight (2%) patients in the nab-paclitaxel-gemcitabine group. INTERPRETATION: Our findings support use of the NALIRIFOX regimen as a possible reference regimen for first-line treatment of mPDAC. FUNDING: Ipsen. TRANSLATION: For the plain language summary see Supplementary Materials section.

Cancer and Hematology Centers of Western Michigan Grand Rapids MI USA

Centre Léon Bérard Lyon France

David Geffen School of Medicine University of California Los Angeles Los Angeles CA USA

Hospital Universitario Miguel Servet Zaragoza Spain

Ipsen Cambridge MA USA

Krankenhaus Nordwest Frankfurt am Main Germany

Masaryk Memorial Cancer Institute Brno Czech Republic

Mayo Clinic Scottsdale AZ USA

MD Anderson Cancer Center Houston TX USA

Memorial Sloan Kettering Cancer Center New York NY USA

National Cancer Center Goyang South Korea

St John of God Subiaco Hospital Subiaco WA Australia

Texas Oncology Baylor Charles A Sammons Cancer Center Dallas TX USA

The Christie NHS Foundation Trust and Division of Cancer Sciences University of Manchester Manchester UK

Università degli studi di Verona and Azienda Ospedaliera Universitaria Integrata Verona Verona Italy

University Hospitals Gasthuisberg Leuven and KU Leuven Leuven Belgium

Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology Barcelona Spain

See more in PubMed

Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol 2019; 10: 10–27. PubMed PMC

National Institutes of Health Surveillance. National Cancer Institute. Epidemiology and end results program. Cancer stat facts: pancreatic cancer. https://seer.cancer.gov/statfacts/html/pancreas.html (accessed March 1, 2023).

Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817–25. PubMed

Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691–703. PubMed PMC

Goldstein D, El Maraghi RH, Hammel P, et al. Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas. J Clin Oncol 2014; 32 (suppl): 178.

De Dosso S, Siebenhüner AR, Winder T, et al. Treatment landscape of metastatic pancreatic cancer. Cancer Treat Rev 2021; 96: 102180. PubMed

Wainberg ZA, Hochster HS, Kim EJ, et al. Open-label, phase I study of nivolumab combined with nab-paclitaxel plus gemcitabine in advanced pancreatic cancer. Clin Cancer Res 2020; 26: 4814–22. PubMed

O’Reilly EM, Oh DY, Dhani N, et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol 2019; 5: 1431–38. PubMed PMC

de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S. Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet 2018; 57: 1229–54. PubMed PMC

Biopharmaceuticals Ipsen. Prescribing information: ONIVYDE™ (irinotecan liposome injection), for intravenous use. February, 2017. https://www.ipsen.com/websites/Ipsen_Online/wp-content/uploads/sites/9/2019/01/21083350/ONIVYDE_USPI.pdf (accessed March 1, 2023).

Drummond DC, Noble CO, Guo Z, Hong K, Park JW, Kirpotin DB. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res 2006; 66: 3271–77. PubMed

Ramanathan RK, Korn RL, Sachdev JC, et al. 261 Lesion characterization with ferumoxytol MRI in patients with advanced solid tumors and correlation with treatment response to MM-398, nanoliposomal irinotecan (nal-IRI). Eur J Cancer 2014; 50: 87.

Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 2016; 387: 545–57. PubMed

Wainberg ZA, Bekaii-Saab T, Boland PM, et al. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. Eur J Cancer 2021; 151: 14–24. PubMed

Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual, 8th edn. New York, NY: Springer Cham, 2017.

Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–47. PubMed

National Cancer Institute. Division of Cancer Treatment & Diagnosis. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50 (accessed March 1, 2023).

Carnevale J, Ko AH. MM-398 (nanoliposomal irinotecan): emergence of a novel therapy for the treatment of advanced pancreatic cancer. Future Oncol 2016; 12: 453–64. PubMed

Prognostic Significance of Inflammation-based Scores in Pancreatic Cancer Patients Treated With Palliative Chemotherapy: A Single Institution Experience

See more in PubMed

ClinicalTrials.gov
NCT04083235